Document text
Principal Investigator: Ellen Elizabeth Sparger
Organization: TENDEL THERAPIES INC.
Fiscal Year: 2024
Award: $571,691
Funding agency: National Institute of Allergy and Infectious Diseases
Tendel’s CoTend-s3B SARS-CoV-2 booster vaccine targets T follicular helper (Tfh) cells to generate
extraordinarily broad and long-lived antibody responses, which are required for resilient vaccines that
maintain protection over long periods. The vaccine candidate incorporates the “s3” targeting moiety, which
induces a potent T follicular helper (Tfh) cell response. This novel, first-in-class adjuvant is fused to the receptor
binding domain (RBD) from the Omicron variant of SARS-CoV-2 (BA.4/BA.5). The combined molecule
simultaneously targets RBD-specific B cells and T cells, and especially local Tfh cells, thus accelerating and
expanding B-cell development. Preclinical non-human primate (NHP) studies have demonstrated extraordinarily
high neutralizing antibody titers that were stable for >10 months when delivered via a low dose of adenovirus
type 35 (Ad35) delivery vector. In contrast, neutralizing antibody responses to control vaccine lacking the s3
moiety (i.e., CoTend-B containing immunogen alone), were diminished to below the level of protection within 6
months, similar to results seen in humans with FDA-approved mRNA vaccines.
In cooperation with academic partners Steve Deeks (UCSF) and Kara Chew (UCLA), Tendel completed
favorable pre-IND interactions for this s3-adjuvanted vaccine and designed a first-in-human trial. In this R44
application we propose several tasks that will provide the needed investigational products and toxicology data,
as well as additional supportive mechanistic data, to support comparative phase-1 testing of CoTend-B and
CoTend-s3B as booster vaccines beginning in early 2024. We will complete GMP-grade production of both
vaccines in amounts sufficient for both GLP safety studies and the planned phase-1 trial. We will test the
technical feasibility of adventitious-agent testing by next-generation sequencing (NGS). Finally, we will use the
vialed vaccine to complete GLP safety studies in macaques while simultaneously gathering high-dimensional
repertoire data to demonstrate superior B-cell recruitment by the s3 adjuvant platform.
The deliverables of this work are fully characterized, GMP-grade vaccine stocks (CoTend-B and CoTend-s3B)
and corresponding safety data that will permit a successful IND application and commencement of clinical trials.
Aim 1. Produce vialed CoTend-B and CoTend-s3B vaccine products according to GMP.
Aim 2. Complete release testing, including adventitious-agent testing by an NGS approach.
Aim 3. Perform GLP toxicology and immunogenicity testing of the vialed product.
The work proposed in this R44 application will enable necessary steps towards the first test in humans of a new
approach to promoting development of antigen-specific B cells. If successful, de-risking of the s3 platform will
provide a transformative new tool that can enable and drive human B-cell development along paths that are
infrequently reached by current vaccines.
Terms: <2019-nCoV vaccine><Acceleration><Adenoviridae><Adenoviruses><Adjuvant><Anti-CD3 Antibody><Antibody Fragments><Antibody Response><Antibody titer measurement><Antigens><B blood cells><B cell><B cells><B-Cell Development><B-Cells><B-Lymphocytes><B-cell><B.1.1.529><CD3><CD3 Antigens><CD3 Complex><CD3 molecule><COVID-19 booster><COVID-19 vaccine><COVID-19 vaccine booster><California><Chimera Protein><Chimeric Proteins><Clinical><Clinical Trials><Complex><Data><Development><Dose><FDA approved><Feedback><Funding><Fusion Protein><Genetic><Genome><Goals><Good Manufacturing Process><Good manufacturing practice><Helper Cells><Helper T-Cells><Helper T-Lymphocytes><Helper-Inducer T-Cells><Helper-Inducer T-Lymphocyte><HuM291><Human><Immunoglobulin Fragments><Inducer Cells><Inducer T-Lymphocytes><Laboratories><Letters><Libraries><Macaca><Macaque><MoAb HuM291><Modern Man><Monoclonal Antibody HuM291><NGS Method><NGS system><NIH><National Institutes of Health><OKT3 antigen><Omicron variant><Persons><Phase><Production><Qualifying><RNA vaccine><RNA-based vaccine><Running><SARS-CoV-2 B.1.1.529><SARS-CoV-2 booster><SARS-CoV-2 omicron><SARS-CoV-2 omicron variant><SARS-CoV-2 vaccine><SARS-CoV-2 vaccine booster><SARS-coronavirus-2 vaccine><Safety><Serial Passage><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe acute respiratory syndrome coronavirus 2 vaccine><T-Cells><T-Lymphocyte><T3 Antigens><T3 Complex><T3 molecule><Techniques><Testing><Toxicology><Transfection><United States National Institutes of Health><Vaccines><Vial><Vial device><Viral><Virus><Work><antibody titering><booster against COVID-19><booster against SARS-CoV-2><booster dose><booster shot><booster vaccine><comparative><coronavirus disease 2019 vaccine><coronavirus disease-19 vaccine><cost><deep sequencing><delivery vector><delivery vehicle><design><designing><developmental><first in man><first-in-human><genome sequencing><high dimensionality><immunogen><immunogenicity><mRNA vaccine><mRNA-based vaccine><manufacture><manufacturing process><manufacturing run><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><neutralizing antibody><new approaches><new vaccines><next gen sequencing><next generation sequencing><next generation vaccines><nextgen sequencing><non-human primate><nonhuman primate><novel><novel approaches><novel strategies><novel strategy><novel vaccines><omicron variant of COVID-19><omicron variant of SARS-CoV-2><particle><phase 1 evaluation><phase 1 testing><phase 1 trial><phase I evaluation><phase I testing><phase I trial><plasmid DNA><pre-clinical><preclinical><production run><programs><receptor binding><receptor bound><recruit><regenerative><resilience><resilient><response><safety study><safety testing><severe acute respiratory syndrome coronavirus 2 B.1.1.529><thymus derived lymphocyte><tool><trial design><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine boost><vaccine candidate><vaccine candidates against SARS-CoV-2><vaccine for novel coronavirus><vaccines preventing COVID><vaccines to prevent COVID><vector><viral detection><virus detection>